Ghisallo Capital Management LLC Invests $2.46 Million in NeuroPace, Inc. $NPCE

Key Points

• Ghisallo Capital Management LLC purchased 200,000 shares of NeuroPace, Inc., valued at approximately $2.46 million, making up about 0.61% of the company’s total stock at the end of the reporting period.
• NeuroPace’s stock has received a mix of analyst ratings, with Zacks Research downgrading it to "hold" while JPMorgan raised its price target from $14 to $16, indicating a general sentiment of moderate buy.
• The company reported a quarterly earnings miss with a loss of $0.26 per share against an expected loss of $0.24, but revenue exceeded expectations at $23.52 million.

Ghisallo Capital Management LLC purchased a new position in NeuroPace, Inc. (NASDAQ:NPCE - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 200,000 shares of the company's stock, valued at approximately $2,458,000. Ghisallo Capital Management LLC owned 0.61% of NeuroPace as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in NPCE. BNP Paribas Financial Markets purchased a new position in NeuroPace in the fourth quarter worth $29,000. GAMMA Investing LLC purchased a new position in NeuroPace in the first quarter worth $53,000. Wells Fargo & Company MN grew its position in NeuroPace by 54.2% in the fourth quarter. Wells Fargo & Company MN now owns 6,483 shares of the company's stock worth $73,000 after acquiring an additional 2,279 shares in the last quarter. MetLife Investment Management LLC purchased a new position in NeuroPace in the fourth quarter worth $103,000. Finally, Cubist Systematic Strategies LLC purchased a new position in NeuroPace in the fourth quarter worth $112,000. Institutional investors own 78.83% of the company's stock.

Analyst Ratings Changes

Several analysts have issued reports on the stock. JPMorgan Chase & Co. upped their price target on shares of NeuroPace from $14.00 to $16.00 and gave the company an "overweight" rating in a research report on Wednesday, May 14th. HC Wainwright assumed coverage on shares of NeuroPace in a research report on Wednesday, May 28th. They set a "buy" rating and a $18.00 price target for the company. Wells Fargo & Company cut their price target on shares of NeuroPace from $17.00 to $15.00 and set an "overweight" rating for the company in a research report on Wednesday, August 13th. Cantor Fitzgerald restated an "overweight" rating and set a $17.00 price target on shares of NeuroPace in a research report on Wednesday, May 14th. Finally, Zacks Research lowered shares of NeuroPace from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, August 13th. Five equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $16.60.

NeuroPace Price Performance

NPCE stock traded up $0.22 during trading on Wednesday, reaching $9.36. The company had a trading volume of 258,142 shares, compared to its average volume of 198,767. NeuroPace, Inc. has a 52 week low of $5.45 and a 52 week high of $18.98. The business has a 50 day moving average of $9.33 and a 200 day moving average of $11.36. The company has a debt-to-equity ratio of 3.02, a current ratio of 5.47 and a quick ratio of 4.51.

NeuroPace (NASDAQ:NPCE - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.02). NeuroPace had a negative net margin of 29.29% and a negative return on equity of 168.61%. The business had revenue of $23.52 million for the quarter, compared to the consensus estimate of $23.08 million. NeuroPace has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that NeuroPace, Inc. will post -1 earnings per share for the current year.

NeuroPace Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.